SRZNW — Surrozen, Inc./DE
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1824893 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 5,000,000 | — | -10,456,000 | -127,505,000 | 120,709,000 | 106,910,000 | 398,856,000 |
| Dec 2025 | 528,000 | — | -12,639,000 | -183,159,000 | 98,726,000 | 89,245,000 | 286,488,000 |
| Sep 2025 | 983,000 | — | -10,885,000 | -71,643,000 | 94,046,000 | 81,335,000 | 117,561,000 |
| Jun 2025 | 983,000 | — | -9,017,000 | 39,746,000 | 102,696,000 | 90,390,000 | 55,582,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-30,244,000
Investing CF
$-128,000
Financing CF
$85,052,000
CapEx
$-128,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
—
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-527,285,000
Inventory
—
Receivables
$208,000
ST Investments
—
EBIT TTM
$-42,092,000
Pretax Income TTM
$-242,026,000
Interest Exp TTM
—
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$7,494,000
EBITDA
$-42,689,000
Free Cash Flow
$-26,107,124
Enterprise Value
—
Total Cash
$106,910,000
Total Debt
$6,778,000
Shares Out
—
Trailing EPS
$-5.70
Book Value
$-19.21
ROE
—
ROA
-22.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 3,477,000 | -42,092,000 | -242,026,000 | 98,726,000 | 286,488,000 | — | -30,244,000 |
| Dec 2024 | 10,655,000 | -25,539,000 | -63,564,000 | 48,467,000 | 69,847,000 | — | -17,628,000 |
| Dec 2023 | 0 | -43,028,000 | -43,042,000 | 46,080,000 | 8,145,000 | — | -40,363,000 |
| Dec 2022 | 12,500,000 | -44,339,000 | -36,004,000 | 89,435,000 | 13,434,000 | — | -44,145,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AMGN | AMGEN INC | $181.31B | $335.94 | — |
| GILD | GILEAD SCIENCES, INC. | $166.04B | $133.73 | — |
| ARGX | ARGENX SE | $50.27B | $808.43 | — |
| RVMD | Revolution Medicines, Inc. | $32.93B | $154.89 | — |
| BIIB | BIOGEN INC. | $28.51B | $193.08 | — |
News headlines (Yahoo Finance, 1h cache)
We're Not Very Worried About Surrozen's (NASDAQ:SRZN) Cash Burn Rate
2026-05-17 14:17 · Yahoo
Surrozen to Present at Upcoming Healthcare Investor Conference
2026-05-12 20:05 · Yahoo
Surrozen Reports First Quarter 2026 Financial Results and Provides Business Update
2026-05-06 20:05 · Yahoo
Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-04-28 20:05 · Yahoo
Avita Medical (RCEL) Soars 14.1%: Is Further Upside Left in the Stock?
2026-04-15 11:06 · Yahoo
Surrozen (SRZN) Surges 5.9%: Is This an Indication of Further Gains?
2026-04-14 13:28 · Yahoo
Surrozen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
2026-03-23 20:05 · Yahoo
Surrozen Reports Third Quarter 2025 Financial Results and Provides Business Update
2025-11-07 21:05 · Yahoo
Surrozen Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-09-04 20:15 · Yahoo
Institutions own 32% of Surrozen, Inc. (NASDAQ:SRZN) shares but private equity firms control 32% of the company
2025-08-30 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.